GE HealthCare’s first quarter was marked by strong revenue growth from its pharmaceutical diagnostics and imaging businesses, as well as robust services demand, but profitability fell short of expectations, contributing to a significant negative market response. CEO Peter Arduini noted that while customer demand and commercial execution remained healthy—particularly in EMEA and global advanced visualization solutions—rising material costs and a product recall in pharmaceutical diagnostics weighed on margins. Management acknowledged disappointment in profit performance, with Arduini stating, “We were disappointed by profit performance in the first quarter, which was impacted by a recall associated with a PDx supplier that has since been resolved.”
Is now the time to buy GEHC? Find out in our full research report (it’s free for active Edge members).
GE HealthCare (GEHC) Q1 CY2026 Highlights:
- Revenue: $5.13 billion vs analyst estimates of $5.02 billion (7.4% year-on-year growth, 2.1% beat)
- Adjusted EPS: $0.99 vs analyst expectations of $1.05 (5.7% miss)
- Adjusted EBITDA: $790 million vs analyst estimates of $855.6 million (15.4% margin, 7.7% miss)
- Management lowered its full-year Adjusted EPS guidance to $4.90 at the midpoint, a 3% decrease
- Operating Margin: 10%, down from 13.2% in the same quarter last year
- Organic Revenue rose 2.9% year on year (beat)
- Market Capitalization: $27.77 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From GE HealthCare’s Q1 Earnings Call
- Vijay Kumar (Evercore ISI) questioned the cadence of revenue acceleration and input cost assumptions; CEO Peter Arduini and CFO Jay Saccaro explained the healthy capital equipment environment and clarified that inflation guidance assumes current elevated trends without additional cushion.
- Joanne Wuensch (Citi) asked about the underperformance in Patient Care Solutions, with Arduini acknowledging that large monitoring deals are weighted to the second half and new product launches should aid recovery.
- Travis Steed (Bank of America Securities) inquired about Flyrcado’s ramp and China’s outlook; Arduini described accelerating dose volumes and noted operational improvements and cautious expectations for China.
- Robert Marcus (JPMorgan) pressed on the level of contingency in profit guidance and the competitive threat from generics in pharmaceutical diagnostics; Saccaro insisted on adequate offsets and continued R&D investment, while Arduini explained current market dynamics and readiness for competitive shifts.
- David Roman (Goldman Sachs) asked for details on commercial strategy for Photon Counting CT and inflation phasing, with Arduini emphasizing differentiation in imaging technology and Saccaro outlining that most inflation impact and mitigation will occur later in the year.
Catalysts in Upcoming Quarters
In the quarters ahead, key factors to watch will be (1) whether GE HealthCare can offset persistent inflationary headwinds through pricing actions and supply chain initiatives, (2) the pace of adoption and revenue contribution from recently launched imaging and radiopharmaceutical products, and (3) early results from the new Advanced Imaging Solutions segment and integration progress with Intelerad. Progress on regulatory milestones for the manganese-based MRI contrast agent will also be a key marker of strategic execution.
GE HealthCare currently trades at $61.05, down from $68.50 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
